BioAtla, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
BCAB$1.74-44.7%Stored close · as of Aug 28, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Years ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Collaboration and other revenue | $2,000 | $11,000 |
| Operating expenses: | ||
| Research and development expense (includes related party amounts of $300 and $2,150 for the years ended December 31, 2025 and 2024, respectively) | 43,573 | 63,095 |
| General and administrative expense | 17,732 | 21,848 |
| Total operating expenses | 61,305 | 84,943 |
| Loss from operations | (59,305) | (73,943) |
| Other income (expense): | ||
| Interest income | 843 | 3,369 |
| Gain on warrant liability | 295 | 807 |
| Loss on PPAs liability | (406) | — |
| Other expense | (1,034) | (9) |
| Total other income (expense) | (302) | 4,167 |
| Consolidated net loss and comprehensive loss | $(59,607) | $(69,776) |
| Net loss per common share, basic and diluted | $(1.01) | $(1.44) |
| Weighted-average shares of common stock outstanding, basic and diluted | 58,827,934 | 48,573,364 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.